NCT06659757View on ClinicalTrials.gov

A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2025

Conditions
Cystic Fibrosis
Interventions
DRUG

KIT2014

KIT2014 will be administered by inhalation with a nebuliser

OTHER

Placebo

Placebo will be administered by inhalation with a nebuliser

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors

Lead Sponsor

Kither Biotech Srl

Collaborators (1)

Avance Clinical Pty Ltd.
All Listed Sponsors
collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

Kither Biotech Srl

INDUSTRY

NCT06659757 - A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects | Biotech Hunter | Biotech Hunter